Is ADPT or BLLN more undervalued in 2026?

CirclFi compares Adaptive Biotechnologies Corpor (ADPT) and BillionToOne, Inc. (BLLN) using 13 institutional-grade valuation models. ADPT has a Quality of Company score of 7.6/10 while BLLN scores 7.9/10.

Which is a better buy — ADPT or BLLN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ADPT and BLLN valuations compare?

ADPT at $15.19 and BLLN at $97.80 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ADPT vs BLLN Valuation Comparison 2026 — Intrinsic Value Analysis

ADPT

Diagnostics & Research

Adaptive Biotechnologies Corpor

Quality

7.6

out of 10

Value Trap

LOW

Price

$15.19

Last close

Models

13/13

Active

BLLN

Diagnostics & Research

BillionToOne, Inc.

Quality

7.9

out of 10

Value Trap

—

Price

$97.80

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	ADPT Fair Value	ADPT Upside	BLLN Fair Value	BLLN Upside
Bayesian DCF	Intrinsic	$2.98	-80.4%	$4.12	-95.8%
Earnings Power Value	Intrinsic	$2.29	-83.9%	$2.92	-97.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ADPT vs BLLN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ADPT vs BLLN — Which Stock Is More Undervalued?

BLLN scores higher with a 7.9/10 quality rating vs ADPT's 7.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Adaptive Biotechnologies Corpor (ADPT) and BillionToOne, Inc. (BLLN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ADPT currently trades at $15.19 with a QOC of 7.6/10, while BLLN trades at $97.80 with a QOC of 7.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).